Clinical Trial Update: A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating ontamalimab for nonalcoholic steatohepatitis with fibrosis (stages 1-4) has been terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Ontamalimab (ontamalimab)

Snippet

Sponsor: Takeda | Conditions: Steatohepatitis | Phase 1 | Status: TERMINATED | Results posted: 2025-08-19